EXOSENS COMPLETES THE CLOSING OF THE ACQUISITION OF CENTRONIC, LEADER IN RADIATION DETECTION SOLUTIONS
01 Agosto 2024 - 8:00AM
UK Regulatory
EXOSENS COMPLETES THE CLOSING OF THE ACQUISITION OF CENTRONIC,
LEADER IN RADIATION DETECTION SOLUTIONS
EXOSENS COMPLETES THE CLOSING OF THE
ACQUISITION OF CENTRONIC, LEADER IN RADIATION DETECTION
SOLUTIONS
PRESS RELEASE
MÉRIGNAC, FRANCE AND CROYDON, UNITED KINGDOM – AUGUST,
1st 2024
-
Exosens announces the closing of the acquisition of
UK-based Centronic, a specialist in radiation detectors and
devices.
- This
strategic merger will enable the combined group to provide high-end
detectors for nuclear market, to Business-to-Business customers,
leveraging advanced technological capabilities.
- The
acquisition will further consolidate Exosens' position in the field
of nuclear instrumentation, in contributing to the development of
the Small Modular Reactor commercial market.
Exosens, a high-tech company
focused on providing mission and performance-critical
amplification, detection and imaging technology, today announces
the closing of the acquisition of UK-based company
Centronic, a specialist developer and manufacturer
of radiation detectors and devices.
By welcoming Centronic, Exosens will provide
unique high-end detectors for nuclear market to their
Business-to-Business customers through mastering of component
manufacturing, a large geographical reach and advanced
technological capabilities.
“With the acquisition of Centronic, we will
consolidate our position in nuclear instrumentation to create a
European leader. It will allow Exosens to offer the best advanced
monitoring solutions to contribute to the development of the Small
Modular Reactor commercial market. Exosens continues to deploy its
accretive bolt-on strategy by acquisition of skilled companies to
accelerate growth ».” commented Jérôme Cerisier, CEO
of Exosens.
Centronic, based in UK with 87 employees, is a
well-established technology leader in the field of radiation
sensors solutions for photonic & ionising radiation including
Gas-Filled detectors, Silicon Photodiodes, Geiger-Müller tubes and
Coil Wound detectors, having a strong position in the worldwide
high-end markets, such as nuclear.
“Created in 1945, Centronic has a strong
background in developing high performance detectors for nuclear,
aerospace and industrial markets. We’re very pleased to join
Exosens and this transaction will allow us to build on that legacy,
accelerate our growth and strengthen our product offer by R&D
joint developments.” stated Neil Foreman, Executive
Chairman of Centronic.
The transaction has been finalized. Terms of the
transaction are not being disclosed.
ABOUT EXOSENS:
Exosens is a high‐tech company, with more than
85 years of experience in the innovation, development,
manufacturing and sale of high‐end electro‐optical technologies in
the field of amplification, detection and imaging. Today, it offers
its customers detection components and solutions such as travelling
wave tubes, advanced cameras, neutron & gamma detectors,
instrument detectors and light intensifier tubes. This allows
Exosens to respond to complex issues in extremely demanding
environments by offering tailor‐made solutions to its customers.
Thanks to its sustained investments, Exosens is internationally
recognized as a major innovator in optoelectronics, with production
and R&D carried out on 10 sites, in Europe and North America
and with over 1,600 employees.
Exosens is listed on compartment A of the
regulated market of Euronext Paris ﴾Ticker: EXENS –
ISIN: FR001400Q9V2﴿ and is a member of Euronext Tech Leaders
segment.
For more information: exosens.com
Forward-looking statements
Certain information included in this press
release are not historical facts but are forward-looking
statements. These forward-looking statements are based on current
beliefs, expectations and assumptions, including, without
limitation, assumptions regarding present and future business
strategies and the environment in which Exosens operates, and
involve known and unknown risks, uncertainties and other factors,
which may cause actual results, performance or achievements to be
materially different from the forward-looking statements included
in this press release.
Media contacts for Exosens:
Brunswick group – exosens@brunswickgroup.com
Laetitia Quignon, + 33 6 83 17 89 13
Nicolas Buffenoir, + 33 6 31 89 36 78
Media contacts for Centronic :
Dr Robert McKeag – rmckeag@centronic.co.uk
- EXOSENS-CENTRONIC - Press release English_VF
Grafico Azioni Exosens (EU:EXENS)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Exosens (EU:EXENS)
Storico
Da Nov 2023 a Nov 2024
